Last updated: August 1, 2026
Prucalopride succinate is a selective, high-affinity 5-HT4 receptor agonist approved for chronic idiopathic constipation in adults. The U.S. product, Motegrity, is marketed by Takeda; Resolor is the principal European brand. Clinical development has moved from pivotal constipation trials toward pediatric use, opioid-induced constipation, gastroparesis and broader gastrointestinal motility disorders. Commercial growth is constrained by generic exposure, competing prescription laxatives and low-cost over-the-counter products.
What is prucalopride succinate approved to treat?
Prucalopride succinate is approved in the United States for chronic idiopathic constipation in adults at a recommended dose of 2 mg once daily. The 1 mg dose is recommended for patients with severe renal impairment. The FDA approved Motegrity on Dec. 14, 2018, under the 505(b)(1) pathway.
In Europe, prucalopride is authorized for symptomatic treatment of chronic constipation in adults when response to laxative therapy is inadequate. The product is marketed primarily as Resolor.
| Attribute |
Details |
| Active ingredient |
Prucalopride succinate |
| Pharmacology |
Selective 5-HT4 receptor agonist |
| U.S. brand |
Motegrity |
| U.S. sponsor |
Takeda Pharmaceuticals |
| Main indication |
Chronic idiopathic constipation |
| U.S. adult dose |
2 mg once daily |
| Dosage forms |
1 mg and 2 mg tablets |
| FDA approval |
December 2018 |
| Regulatory pathway |
505(b)(1) new drug application |
| Principal competitors |
Linaclotide, plecanatide, lubiprostone, tenapanor, polyethylene glycol and stimulant laxatives |
The FDA label identifies abdominal pain, nausea, diarrhea, headache, abdominal distension, dizziness, fatigue and vomiting as common adverse reactions. The label also includes warnings concerning suicidal ideation and behavior, mood changes and hypersensitivity reactions.[1]
What clinical trials support prucalopride efficacy?
The pivotal development program evaluated stool frequency, bowel-movement consistency, straining, constipation symptoms and patient-reported treatment response. Across the phase 3 program, prucalopride increased the proportion of patients achieving at least three spontaneous complete bowel movements per week and improved disease-related symptoms compared with placebo.[1,2]
Phase 3 chronic idiopathic constipation trials
The clinical program included large randomized, double-blind, placebo-controlled studies in adults with chronic constipation. The primary endpoint generally used the regulatory responder definition of at least three spontaneous complete bowel movements per week, with an increase of at least one from baseline.
Key findings reported in the FDA review and published studies included:
- Higher weekly spontaneous complete bowel movement frequency than placebo.
- Improvement in straining and stool consistency.
- Earlier treatment response in some patients.
- Improvements in constipation-related quality-of-life measures.
- A generally manageable gastrointestinal adverse-event profile.
The pivotal studies also showed that treatment response was clinically meaningful for a subset of patients rather than universal across the treated population. This limits the product’s commercial differentiation in a category with multiple alternatives.
Cardiovascular safety evaluation
Earlier 5-HT4 agonists raised cardiovascular safety concerns, making cardiovascular assessment central to prucalopride development. Prucalopride has greater receptor selectivity than older agents such as cisapride and tegaserod. The FDA review did not identify a cardiovascular safety signal comparable to that associated with nonselective 5-HT4 agonists, although postmarketing monitoring remains relevant.[1]
A pooled cardiovascular safety analysis of more than 1,700 patients treated with prucalopride found no clinically relevant increase in major adverse cardiovascular events compared with placebo or active comparators.[3] The dataset was not designed to establish cardiovascular benefit.
What are the latest clinical trials for prucalopride?
The most commercially relevant research areas are pediatric constipation, opioid-induced constipation and upper gastrointestinal motility disorders. The evidence base is strongest for chronic idiopathic constipation in adults.
Pediatric chronic constipation
Pediatric studies have evaluated whether prucalopride can increase stool frequency and reduce constipation symptoms in children and adolescents. Results have been less commercially decisive than the adult program. Pediatric constipation has a strong generic and behavioral-treatment component, and regulators require age-specific safety and efficacy evidence.
Prucalopride does not have broad U.S. FDA approval for pediatric chronic idiopathic constipation. Pediatric use therefore remains a development and off-label opportunity rather than an established U.S. label expansion.
Opioid-induced constipation
Prucalopride has been studied in opioid-induced constipation because its prokinetic mechanism could improve bowel transit in patients receiving chronic opioid therapy. The market is competitive, with approved products including methylnaltrexone, naldemedine, naloxegol and lubiprostone.
Clinical results have not displaced peripherally acting mu-opioid receptor antagonists as the preferred drug class for opioid-induced constipation. The principal commercial barrier is mechanism-specific competition from drugs with dedicated regulatory labels and established reimbursement pathways.
Gastroparesis and upper gastrointestinal motility
Small clinical studies have evaluated prucalopride in gastroparesis and related motility disorders. A randomized crossover study in patients with gastroparesis reported improvements in some symptom and gastric-emptying measures, but the evidence remains exploratory and does not establish an approved indication.[4]
Gastroparesis is a potentially attractive expansion market because treatment options remain limited. Prucalopride would face competition from metoclopramide, domperidone where available, erythromycin and investigational agents. A commercially meaningful expansion would require larger, well-controlled trials using endpoints accepted by regulators and payers.
Combination and disease-specific studies
Published research has also examined prucalopride in conditions such as Parkinson’s disease-related constipation, spinal cord injury, multiple sclerosis and constipation associated with other motility disorders. These studies are generally small, investigator-led or disease-specific. They have not produced an approved indication in the United States.
What is the FDA regulatory status of Motegrity?
Motegrity has full FDA approval for adult chronic idiopathic constipation. It is not an accelerated-approval product, and the FDA label does not depend on a confirmatory trial for continued approval.
| Regulatory item |
Status |
| FDA approval |
Active |
| Approval date |
Dec. 14, 2018 |
| U.S. indication |
Chronic idiopathic constipation in adults |
| NDA holder |
Takeda Pharmaceuticals |
| Pediatric indication |
Not broadly approved |
| REMS |
No product-specific REMS identified in the FDA label |
| Reference product |
Motegrity tablets |
| Orange Book status |
Listed as the reference drug; patent listing should be checked against the current FDA Orange Book before litigation or launch decisions |
Motegrity’s regulatory value is concentrated in the existing adult indication. A new indication for gastroparesis, opioid-induced constipation or pediatric constipation would require supplemental clinical and regulatory work.
What patents protect prucalopride succinate?
Prucalopride is a small molecule with a mature patent history. The original composition-of-matter and early development patents have largely reached the end of their enforceable life in major markets. Protection may still exist in selected jurisdictions through later-filed formulation, salt, polymorph, process or method-of-use patents, but those rights require jurisdiction-specific verification.
The principal patent-risk points are:
- Composition of matter: Core molecule protection is generally the oldest and most likely to have expired or be near expiry.
- Succinate salt: Salt-related claims may have provided additional protection, but salt patents usually face validity and obviousness challenges when the active compound is known.
- Solid-state and formulation claims: These can protect tablet composition, polymorphs or manufacturing parameters, although their scope is narrower than composition claims.
- Method-of-use claims: Claims directed to chronic idiopathic constipation, dosing or patient subgroups may be listed or asserted, but their enforceability depends on claim language and prescribing conduct.
- Manufacturing patents: Process patents can create supply-chain friction but usually do not block all generic routes if alternative processes are available.
A definitive freedom-to-operate opinion should rely on the current Orange Book, USPTO records, European Patent Register data and national registers. The commercial conclusion is clearer: prucalopride has substantially lower blocking-patent value than a recently launched small-molecule product.
When does prucalopride lose exclusivity?
U.S. regulatory exclusivity was scheduled to run for five years from the 2018 approval date, subject to statutory adjustments. The five-year new chemical entity exclusivity period therefore ended in December 2023. Pediatric exclusivity could extend protection if awarded for qualifying studies, but no broad pediatric extension should be assumed without an FDA record confirming it.
Exclusivity timeline
| Event |
Date or period |
| U.S. approval of Motegrity |
December 2018 |
| Standard five-year NCE exclusivity |
Through approximately December 2023 |
| Generic ANDA eligibility |
Potentially after NCE exclusivity, subject to patents and certifications |
| Patent expiry |
Patent-family and jurisdiction dependent |
| Generic launch timing |
Dependent on ANDA approval, litigation, settlement and supply readiness |
The end of NCE exclusivity does not automatically create generic launch permission. A listed patent can support a Paragraph IV challenge, a 30-month stay or litigation. Conversely, a patent expiry does not ensure immediate generic supply because ANDA review, manufacturing qualification and reimbursement contracting can delay launch.
Which companies are challenging prucalopride exclusivity?
The principal potential challengers are generic manufacturers that already participate in the gastrointestinal market, including Teva, Viatris, Sandoz, Amneal, Lupin, Dr. Reddy’s Laboratories and Sun Pharma. Publicly visible market participation does not by itself establish that any company has filed a Paragraph IV certification for prucalopride.
A Paragraph IV strategy would typically challenge one or more listed patents while seeking FDA approval before patent expiration. The commercial incentive is moderate:
- The drug has a differentiated mechanism but a limited indication.
- Chronic constipation has substantial generic and OTC competition.
- Tablets are relatively straightforward to manufacture.
- Payer substitution could reduce branded pricing rapidly after generic entry.
- A first generic could capture disproportionate share if only a small number of ANDAs are approved.
What is the Orange Book status of prucalopride?
Motegrity is the U.S. reference product. Orange Book analysis should focus on:
- Active ingredient and dosage-form listings.
- Any patents listed for the 1 mg and 2 mg tablets.
- Patent-use codes tied to chronic idiopathic constipation.
- Whether listed patents cover the product, formulation or method of use.
- The timing of any Paragraph IV notice and associated district-court litigation.
The Orange Book is the operative source for FDA-listed patents, while the FDA label establishes the approved indication and dosage. Patent-family records outside the Orange Book may remain relevant to manufacturing or commercial negotiations but do not necessarily block an ANDA.
How strong is the prucalopride patent estate?
The estate is moderate to weak from a late-life commercial perspective. The molecule has meaningful regulatory and clinical differentiation, but its earliest patents are mature and the core product is a conventional oral tablet.
| Patent category |
Relative strength |
Commercial assessment |
| Core molecule |
Low at current lifecycle stage |
Likely mature or expired in major markets |
| Succinate salt |
Low to moderate |
Potentially useful but vulnerable to validity challenges |
| Tablet formulation |
Moderate |
Narrower scope; design-around risk |
| Method of use |
Moderate |
Depends on claim construction and label conduct |
| Manufacturing process |
Moderate |
Can complicate supply but rarely creates absolute exclusion |
| Pediatric indication |
Potentially moderate |
Requires regulatory approval and qualifying exclusivity |
| Gastroparesis use |
Unestablished |
No commercial protection without an approved and enforceable claim |
The most valuable remaining IP would be a valid, Orange Book-listed formulation or method-of-use patent with claims difficult to design around. Broad market protection is unlikely to come from the original molecule alone.
What is the market size for prucalopride?
No standalone, audited global revenue figure for prucalopride is consistently disclosed by Takeda. Motegrity sales are not generally reported as a separate major product line in Takeda’s public financial reporting. Third-party market reports often aggregate prucalopride with constipation drugs or provide estimates that differ materially by geography and definition.
The product’s addressable market is the prescription segment of chronic idiopathic constipation, not the entire constipation market. Most constipation treatment occurs through OTC products, including polyethylene glycol, fiber, senna and bisacodyl.
Market drivers
- Persistent under-treatment of chronic constipation.
- Preference for oral, once-daily prescription therapy.
- Need for alternatives after inadequate response to conventional laxatives.
- Increased diagnosis of gastrointestinal motility disorders.
- Potential label expansion into pediatric constipation or gastroparesis.
- Physician familiarity with selective 5-HT4 agonism.
Market constraints
- Low-cost OTC laxatives.
- Linaclotide and plecanatide in CIC and irritable bowel syndrome with constipation.
- Lubiprostone and tenapanor.
- Generic substitution after loss of exclusivity.
- Reimbursement controls and step therapy.
- Limited evidence outside adult chronic idiopathic constipation.
- Safety monitoring related to psychiatric warnings in the U.S. label.
What is the prucalopride market forecast through 2030?
A reasonable base-case forecast for the global branded and generic prucalopride market is low- to mid-single-digit annual growth through 2030, with value growth moderated by generic erosion. Under a modeled scenario, global sales could reach approximately $200 million to $300 million by 2030, compared with an estimated low-hundreds-of-millions market in the early 2020s.
| Scenario |
2024-2030 growth assumption |
2030 market outcome |
| Downside |
Decline after generic entry |
$100 million-$170 million |
| Base case |
Low- to mid-single-digit volume growth, price erosion |
$200 million-$300 million |
| Upside |
Gastroparesis or pediatric expansion plus delayed generic erosion |
$350 million-$500 million |
These projections represent market scenarios rather than reported company guidance. The base case assumes continued adult CIC demand, declining branded price after generic competition and no major global indication expansion.
Regional outlook
| Region |
Commercial outlook |
| United States |
Highest price opportunity, but strongest generic and payer risk |
| Europe |
Mature use of Resolor and greater generic-price pressure |
| Japan |
Potentially attractive specialty GI market, subject to local reimbursement and approval status |
| China |
Growth depends on local registration, hospital access and domestic generic competition |
| Latin America |
Volume opportunity with lower net pricing |
| Middle East and other markets |
Distributor-led, fragmented opportunities |
What generic entry risks exist for Motegrity?
The highest-risk scenario is a first generic launch shortly after ANDA approval or patent settlement. A single generic could trigger rapid formulary substitution because prucalopride is a conventional tablet and patients can usually switch without administration training.
A likely launch sequence is:
- ANDA filing after NCE exclusivity expires.
- Paragraph IV certification against any remaining listed patents.
- Patent litigation or a negotiated settlement.
- Tentative approval if a listed patent remains unresolved.
- Final approval after patent resolution or expiry.
- Rapid price reduction and pharmacy substitution.
Brand retention would depend on payer contracting, patient familiarity, clinical preference for Motegrity and the number of approved generics. The product has no device-related switching barrier.
How does prucalopride compare with competing constipation drugs?
| Drug |
Class |
Main approved use |
Competitive position |
| Prucalopride |
Selective 5-HT4 agonist |
CIC |
Prokinetic option after laxative failure |
| Linaclotide |
Guanylate cyclase-C agonist |
CIC and IBS-C |
Strong branded and clinical presence |
| Plecanatide |
Guanylate cyclase-C agonist |
CIC and IBS-C |
Similar mechanism to linaclotide |
| Lubiprostone |
Chloride channel activator |
CIC, IBS-C and OIC in selected populations |
Established but gastrointestinal adverse effects |
| Tenapanor |
Sodium/hydrogen exchanger 3 inhibitor |
IBS-C |
Narrower, symptom-focused positioning |
| Polyethylene glycol |
Osmotic laxative |
OTC constipation |
Low cost and broad use |
| Naldemedine |
Peripheral mu-opioid antagonist |
OIC |
Stronger fit for opioid-induced constipation |
Prucalopride’s differentiation is its direct effect on colonic motility. Its weakness is that many patients and payers begin with less expensive laxatives or use competing prescription drugs with broader constipation-related labels.
What licensing deals and partnerships affect prucalopride?
Takeda acquired the relevant Resolor rights and assets through its broader acquisition of Movetis in 2010. The transaction gave Takeda access to prucalopride and Movetis’ gastrointestinal pipeline, including European commercialization rights and the product’s established regulatory position.[5]
No major recent prucalopride licensing transaction has materially altered the global competitive structure. Commercial rights remain primarily associated with Takeda in the United States and selected international markets, while regional commercialization arrangements may differ by country.
What patent litigation affects prucalopride?
The key litigation question is whether any active Orange Book patent remains capable of triggering a 30-month stay against an ANDA. Publicly available information does not indicate a major, market-defining U.S. patent dispute comparable with litigation surrounding high-revenue specialty drugs.
The litigation risk is therefore concentrated in:
- Paragraph IV notices involving listed formulation or method patents.
- Challenges to patent validity or enforceability.
- Settlement terms controlling the first generic launch date.
- Supply and manufacturing disputes involving active pharmaceutical ingredient sources.
- National patent proceedings in Europe and other regulated markets.
A settlement could preserve branded revenue longer than the nominal end of NCE exclusivity while still permitting an authorized generic or limited generic entry.
Key Takeaways
- Prucalopride succinate is approved in the U.S. as Motegrity for chronic idiopathic constipation in adults.
- The strongest clinical evidence supports increased spontaneous complete bowel movements and improved constipation symptoms.
- Pediatric constipation, opioid-induced constipation and gastroparesis remain the principal expansion areas, but none has displaced adult CIC as the commercial core.
- U.S. five-year NCE exclusivity ended approximately in December 2023.
- The original composition-of-matter estate is mature; remaining formulation, salt, process and method patents require current-register review.
- Generic entry is commercially feasible because the product is a conventional oral tablet with no device-dependent switching barrier.
- The base-case global market forecast is approximately $200 million to $300 million by 2030, with substantial downside after generic launch.
- Takeda remains the central commercial rights holder, following its acquisition of Movetis.
- Prucalopride’s main competitive advantage is selective prokinetic activity; its main commercial liabilities are generic exposure, OTC substitution and payer restrictions.
FAQs
Is prucalopride the same drug as Motegrity?
Yes. Motegrity is the U.S. brand for prucalopride succinate tablets.
Can prucalopride be used for gastroparesis?
Prucalopride has been studied experimentally in gastroparesis, but it is not broadly FDA-approved for that indication.
Is prucalopride a biologic or a small-molecule drug?
It is a synthetic small-molecule drug. Biosimilar regulation does not apply; generic-drug regulation through an ANDA is the relevant pathway.
Does prucalopride have an opioid-induced constipation label?
Prucalopride is not the principal U.S.-approved product for opioid-induced constipation. Peripherally acting mu-opioid receptor antagonists have the stronger regulatory position in that market.
What would most increase the value of the prucalopride franchise?
A successful FDA-approved expansion into gastroparesis or pediatric constipation would provide the largest potential value increase, provided the sponsor obtained enforceable regulatory or patent protection and demonstrated differentiated reimbursement value.
References
-
U.S. Food and Drug Administration. (2018). Motegrity (prucalopride) prescribing information. FDA.
-
Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L. (2008). A placebo-controlled trial of prucalopride for severe chronic constipation. New England Journal of Medicine, 358(22), 2344-2354.
-
Camilleri, M., De Maeyer, J. H., & McKinsey, J. (2016). Safety assessment of prucalopride in patients with chronic constipation. Neurogastroenterology & Motility, 28(12), 1867-1878.
-
Carbone, F., Van den Houte, K., Clevers, E., Andrews, C. N., Papathanasopoulos, A., Holvoet, L., Van Oudenhove, L., & Tack, J. (2019). Prucalopride in gastroparesis: A randomized placebo-controlled crossover study. American Journal of Gastroenterology, 114(8), 1265-1274.
-
Takeda Pharmaceutical Company. (2010). Takeda completes acquisition of Nycomed. Corporate transaction announcement.
